Iovance Biotherapeutics updated results from its Phase 2 IOV-LUN-202 trial showing a 24.6% objective response rate in 69 patients with non-squamous metastatic non-small-cell lung cancer (mNSCLC). A biomarker-enriched subgroup with KRAS wild-type tumors showed a higher 59.1% response rate, guiding a new precision tumor infiltrating lymphocyte (TIL) therapy strategy. Enrollment is completing for cohorts supporting a supplemental biologics license application planned for 2027. Iovance will start a biomarker-enriched study, POSITILITY, in November 2026 to further evaluate this targeted approach.
Iovance Biotherapeutics has a market cap of $6.72 billion and an enterprise value of $6.65 billion as of October 29, 2026, 18:11 WIB. On Pluang, its stock price is USD 13.40, down 9.52% for the day with a volume of 8,779,721 shares traded. The platform shows a strong sell sentiment with 100% of order activity being sell orders, reflecting cautious investor behavior at this time.
Iovance Biotherapeutics will host a webcast on October 29, 2026, to present positive Phase 2 results of its lifileucel TIL therapy for previously treated metastatic non-small cell lung cancer (mNSCLC). This therapy represents a novel one-time treatme...
Iovance Biotherapeutics, a biotech company specializing in tumor infiltrating lymphocyte (TIL) therapies for cancer, will announce its third quarter 2026 financial results and corporate updates on November 5, 2026. The company is known for its FDA-ap...
Iovance Biotherapeutics announced that lifileucel, a one-time TIL cell therapy, achieved a 50% confirmed objective response rate in a pilot trial for advanced soft tissue sarcomas, specifically undifferentiated pleomorphic sarcoma (UPS) and dediffere...
